清脆的
基因组编辑
T细胞受体
多路复用
T细胞
癌症研究
基因
癌症
Cas9
生物
计算生物学
免疫系统
生物信息学
免疫学
遗传学
作者
Edward A. Stadtmauer,Joseph A. Fraietta,Megan M. Davis,Adam D. Cohen,Kristy Weber,Eric Lancaster,Patricia Mangan,Irina Kulikovskaya,Minnal Gupta,Fang Chen,Lifeng Tian,Vanessa Gonzalez,Jun Xu,In-Young Jung,J. Joseph Melenhorst,Gabriela Plesa,Joanne Shea,Tina Matlawski,Amanda Cervini,Avery L. Gaymon
出处
期刊：Science
[American Association for the Advancement of Science]
日期：2020-02-07
卷期号：367 (6481)
被引量：1127
标识
DOI：10.1126/science.aba7365
摘要
CRISPR-Cas9 gene editing provides a powerful tool to enhance the natural ability of human T cells to fight cancer. We report a first-in-human phase 1 clinical trial to test the safety and feasibility of multiplex CRISPR-Cas9 editing to engineer T cells in three patients with refractory cancer. Two genes encoding the endogenous T cell receptor (TCR) chains, TCRα (
科研通智能强力驱动
Strongly Powered by AbleSci AI
迟大猫
劲秉
请叫我风吹麦浪
科研小民工
QOP
迷人秋烟
cdercder
美好乐松
昏睡的蟠桃
Singularity
maox1aoxin
默默地读文献
nozero
Grayball
VDC
pluto
子车茗
1+1
爱静静
1351567822
皖公网安备34019202002308
